SK Hynix Soars 13% in Nasdaq Debut After Record $26.5 Billion IPO 
Yaskawa Electric Shares Slide as Weak Profit Overshadows Strong AI Demand 
Genesis Minerals to Acquire Vault in A$5.6 Billion Deal After Regis Withdraws 
Goldman AM Sees Strong Buyout Opportunities in Japan, South Korea and Australia 
Mastercard Explores Sale of Majority Stake in UK Payments Firm Vocalink: Report 
Australia Flags Child Safety Gaps at Apple, Meta, Google Over Online Sexual Extortion 
Apple Sues OpenAI, Former Employees Over Alleged Trade Secret Theft 
Morgan Stanley Says China’s Reusable Rocket Progress Poses Long-Term Challenge to SpaceX 
Nippon Paint Reportedly Offers Up to €7.5 Billion for Akzo Nobel Decorative Paints Business 
AstraZeneca Shares Sink After Wainua Trial Misses Key Heart Disease Goal 
OpenAI Executive Fidji Simo to Step Down Amid Health Challenges Ahead of IPO 
Muji Owner Ryohin Keikaku Stock Soars After Raising Full-Year Earnings Forecast 
Oppenheimer Sees CNH Industrial as Top 2026 Agriculture Stock Pick on Dealer Consolidation Strategy 
Stellantis Q2 Vehicle Shipments Rise 10% as North America Drives Growth 
SoftBank Corp Partners With Sierra to Expand AI Customer Support Across Japan 
Morgan Stanley Names Marks & Spencer Top European Retail Pick, Sees Strong Upside 
Nvidia Tightens AI Chip Sales in Asia With Stricter Customer Approval Process 
WORCESTER, Mass., Dec. 07, 2015 (GLOBE NEWSWIRE) -- Nemucore Medical Innovations, Inc., a privately held, clinical-stage biopharmaceutical company dedicated to the development of therapies targeting multi-drug resistant cancers with a special emphasis on highly lethal women’s cancers, today announced the closing of a Series A financing round. Nemucore plans to use the proceeds of the financing to advance NMI-900, a potential "best-in-class" therapeutic into a Phase 2b trial in ovarian cancer, the development and expansion of its innovative oncology pipeline and for general corporate purposes. Financial terms were not disclosed.
“We are pleased to close this financing, which is key to progressing our lead program into the next stage of clinical development,” said Timothy P. Coleman, Ph.D., Chairman, Chief Executive Officer and President of Nemucore. “This financing recognizes the capital efficiency of our organization, as we have successfully advanced novel therapies into the clinic for difficult-to-treat cancers. We believe the support of our investors is a strong endorsement of the leadership team and positions Nemucore’s assets for strategic growth and investment.”
About Nemucore Medical Innovations, Inc.
Nemucore Medical Innovations, Inc. is a privately held, clinical-stage biopharmaceutical company dedicated to the development of therapies targeting multi-drug resistant cancers with a special emphasis on highly lethal women’s cancers. Nemucore's most advanced candidate NMI-900, a potential "best-in-class" therapeutic for the treatment of ovarian cancer, is expected to begin a Phase 2b clinical trial in mid-2016. Two additional candidates are anticipated to enter clinical trial development later in 2016, targeting a variety of difficult-to-treat oncology indications, including breast, non-small cell lung cancer (NSCLC), myelodysplastic syndrome (MDS) and other cancers. For more information, please visit our website at www.nemucore.com.
Tim Coleman (investors) Nemucore Medical Innovations (508) 762-1017 BCC Partners (media) Karen Bergman (650) 323-1717 [email protected] Jen LaVin (207) 360-0473 [email protected]
